NCT03494504View on ClinicalTrials.gov

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

March 30, 2018

Primary Completion Date

November 5, 2018

Study Completion Date

November 5, 2018

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) administered once.

DRUG

Reproxalap Ophthalmic Solution (0.5%)

Reproxalap Ophthalmic Solution (0.5%) administered once.

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution administered once.

Trial Locations (7)

21078

Seidenberg Protzko Eye Associates, Havre de Grace

78209

Eye Clinics of South Texas, San Antonio

78229

R & R Research, LLC, San Antonio

85032

Cornea Consultants of Arizon, Phoenix

90505

East West Eye Institute, Torrance

95819

Eye Site Sacramento, Sacramento

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY

NCT03494504 - ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter